{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,30]],"date-time":"2026-07-30T11:23:07Z","timestamp":1785410587388,"version":"3.56.0"},"reference-count":46,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2026,3,1]],"date-time":"2026-03-01T00:00:00Z","timestamp":1772323200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,3,1]],"date-time":"2026-03-01T00:00:00Z","timestamp":1772323200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/100017950","name":"Shanghai Municipal Health Commission","doi-asserted-by":"publisher","award":["2023ZZ02005"],"award-info":[{"award-number":["2023ZZ02005"]}],"id":[{"id":"10.13039\/100017950","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100012166","name":"National Key Research and Development Program of China","doi-asserted-by":"publisher","award":["2022YFC2503700"],"award-info":[{"award-number":["2022YFC2503700"]}],"id":[{"id":"10.13039\/501100012166","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100012166","name":"National Key Research and Development Program of China","doi-asserted-by":"publisher","award":["2022YFC2503705"],"award-info":[{"award-number":["2022YFC2503705"]}],"id":[{"id":"10.13039\/501100012166","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100008750","name":"Shanghai Municipal Hospital Development Center","doi-asserted-by":"publisher","award":["SHDC2020CR1004A"],"award-info":[{"award-number":["SHDC2020CR1004A"]}],"id":[{"id":"10.13039\/501100008750","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","ejso.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Journal of Surgical Oncology"],"published-print":{"date-parts":[[2026,3]]},"DOI":"10.1016\/j.ejso.2026.111407","type":"journal-article","created":{"date-parts":[[2026,1,15]],"date-time":"2026-01-15T07:15:50Z","timestamp":1768461350000},"page":"111407","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":2,"title":["Transarterial chemoembolization combined with immune checkpoint inhibitors and anti-VEGF agents for intermediate HCC: a multicenter study"],"prefix":"10.1016","volume":"52","author":[{"given":"Wei-Yi","family":"Jiang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jin-Kai","family":"Feng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bin","family":"Zhou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Si-Si","family":"Ren","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yu-Chao","family":"Hou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fang-Fang","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yan-Jun","family":"Xiang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zong-Han","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rong-Chen","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yun-Feng","family":"Shan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chao","family":"Liang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hong-Kun","family":"Zhou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lin","family":"Gong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shu-Qun","family":"Cheng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"3","key":"10.1016\/j.ejso.2026.111407_bib1","first-page":"209","article-title":"Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries","volume":"71","author":"Sung","year":"2021","journal-title":"CA Cancer J Clin"},{"issue":"10360","key":"10.1016\/j.ejso.2026.111407_bib2","doi-asserted-by":"crossref","first-page":"1345","DOI":"10.1016\/S0140-6736(22)01200-4","article-title":"Hepatocellular carcinoma","volume":"400","author":"Vogel","year":"2022","journal-title":"Lancet"},{"issue":"1","key":"10.1016\/j.ejso.2026.111407_bib3","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1038\/s41392-024-02075-w","article-title":"Hepatocellular carcinoma: signaling pathways and therapeutic advances","volume":"10","author":"Zheng","year":"2025","journal-title":"Signal Transduct Targeted Ther"},{"key":"10.1016\/j.ejso.2026.111407_bib4","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2024.1430991","article-title":"New advances in the treatment of intermediate and advanced hepatocellular carcinoma","volume":"14","author":"Zhonghao","year":"2024","journal-title":"Front Oncol"},{"issue":"1","key":"10.1016\/j.ejso.2026.111407_bib5","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejso.2023.107313","article-title":"Hepatocellular carcinoma","volume":"50","author":"Dopazo","year":"2024","journal-title":"Eur J Surg Oncol"},{"issue":"1","key":"10.1016\/j.ejso.2026.111407_bib6","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1016\/j.cld.2022.08.004","article-title":"Hepatocellular carcinoma: new developments","volume":"27","author":"Ganesan","year":"2023","journal-title":"Clin Liver Dis"},{"issue":"3","key":"10.1016\/j.ejso.2026.111407_bib7","doi-asserted-by":"crossref","first-page":"420","DOI":"10.1038\/s41416-024-02684-w","article-title":"The association between tumour heterogeneity and immune evasion mechanisms in hepatocellular carcinoma and its clinical implications","volume":"131","author":"Chen","year":"2024","journal-title":"Br J Cancer"},{"issue":"1","key":"10.1016\/j.ejso.2026.111407_bib8","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1038\/s41392-022-01248-9","article-title":"Blockade of NMT1 enzymatic activity inhibits N-myristoylation of VILIP3 protein and suppresses liver cancer progression","volume":"8","author":"Tan","year":"2023","journal-title":"Signal Transduct Targeted Ther"},{"issue":"5","key":"10.1016\/j.ejso.2026.111407_bib9","doi-asserted-by":"crossref","first-page":"522","DOI":"10.1159\/000537915","article-title":"Disease etiology impact on outcomes of hepatocellular carcinoma patients treated with atezolizumab plus Bevacizumab: a real-world, multicenter study","volume":"13","author":"Rossari","year":"2024","journal-title":"Liver Cancer"},{"issue":"5","key":"10.1016\/j.ejso.2026.111407_bib10","doi-asserted-by":"crossref","first-page":"369","DOI":"10.1093\/oncolo\/oyad343","article-title":"Clinical characteristics, treatment patterns, and outcomes of patients with locally advanced\/metastatic hepatocellular carcinoma treated at the veterans health administration","volume":"29","author":"Alkadimi","year":"2024","journal-title":"Oncologist"},{"issue":"9","key":"10.1016\/j.ejso.2026.111407_bib11","doi-asserted-by":"crossref","first-page":"2055","DOI":"10.1111\/liv.15101","article-title":"Changes in therapeutic options for hepatocellular carcinoma in Asia","volume":"42","author":"Ogasawara","year":"2022","journal-title":"Liver Int"},{"issue":"1","key":"10.1016\/j.ejso.2026.111407_bib12","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1186\/s12929-024-01011-y","article-title":"Translational research on drug development and biomarker discovery for hepatocellular carcinoma","volume":"31","author":"Chew","year":"2024","journal-title":"J Biomed Sci"},{"issue":"2","key":"10.1016\/j.ejso.2026.111407_bib13","doi-asserted-by":"crossref","DOI":"10.1002\/mco2.474","article-title":"Hepatocellular carcinoma: signaling pathways, targeted therapy, and immunotherapy","volume":"5","author":"Luo","year":"2020","journal-title":"MedComm"},{"issue":"3","key":"10.1016\/j.ejso.2026.111407_bib14","doi-asserted-by":"crossref","first-page":"513","DOI":"10.1158\/1078-0432.CCR-21-1258","article-title":"NASH and hepatocellular carcinoma: immunology and immunotherapy","volume":"29","author":"Pinter","year":"2023","journal-title":"Clin Cancer Res"},{"issue":"3","key":"10.1016\/j.ejso.2026.111407_bib15","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1159\/000528356","article-title":"Outcomes of salvage surgery for initially unresectable hepatocellular carcinoma converted by transcatheter arterial chemoembolization combined with lenvatinib plus Anti-PD-1 antibodies: a multicenter retrospective study","volume":"12","author":"Wu","year":"2023","journal-title":"Liver Cancer"},{"issue":"18","key":"10.1016\/j.ejso.2026.111407_bib16","doi-asserted-by":"crossref","first-page":"3650","DOI":"10.1158\/1078-0432.CCR-23-0581","article-title":"A phase I\/IIa trial of Yttrium-90 radioembolization in combination with durvalumab for locally advanced unresectable hepatocellular carcinoma","volume":"29","author":"Lee","year":"2023","journal-title":"Clin Cancer Res"},{"issue":"5","key":"10.1016\/j.ejso.2026.111407_bib17","doi-asserted-by":"crossref","first-page":"1439","DOI":"10.1097\/JS9.0000000000000344","article-title":"Liver resection versus transarterial chemoembolisation for the treatment of intermediate hepatocellular carcinoma: a systematic review and meta-analysis","volume":"109","author":"Bogdanovic","year":"2023","journal-title":"Int J Surg"},{"issue":"2","key":"10.1016\/j.ejso.2026.111407_bib18","doi-asserted-by":"crossref","first-page":"230","DOI":"10.3350\/cmh.2022.0421","article-title":"Clinical practice guidelines and real-life practice in hepatocellular carcinoma: a Taiwan perspective","volume":"29","author":"Su","year":"2023","journal-title":"Clin Mol Hepatol"},{"issue":"1","key":"10.1016\/j.ejso.2026.111407_bib19","doi-asserted-by":"crossref","first-page":"873","DOI":"10.1186\/s12885-023-11389-x","article-title":"Improved clinical outcomes in advanced hepatocellular carcinoma treated with transarterial chemoembolization plus atezolizumab and bevacizumab: a bicentric retrospective study","volume":"23","author":"Cao","year":"2023","journal-title":"BMC Cancer"},{"key":"10.1016\/j.ejso.2026.111407_bib20","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2022.1057560","article-title":"Transarterial chemoembolization plus apatinib with or without camrelizumab for unresected hepatocellular carcinoma: a two-center propensity score matching study","volume":"12","author":"Zhu","year":"2022","journal-title":"Front Oncol"},{"issue":"1","key":"10.1016\/j.ejso.2026.111407_bib21","doi-asserted-by":"crossref","first-page":"328","DOI":"10.1038\/s41392-025-02427-0","article-title":"Transarterial chemoembolization plus atezolizumab and bevacizumab in patients with intermediate hepatocellular carcinoma: a single-arm, phase 2 trial","volume":"10","author":"Wang","year":"2025","journal-title":"Signal Transduct Targeted Ther"},{"issue":"10474","key":"10.1016\/j.ejso.2026.111407_bib22","doi-asserted-by":"crossref","first-page":"216","DOI":"10.1016\/S0140-6736(24)02551-0","article-title":"Durvalumab with or without bevacizumab with transarterial chemoembolisation in hepatocellular carcinoma (EMERALD-1): a multiregional, randomised, double-blind, placebo-controlled, phase 3 study","volume":"405","author":"Sangro","year":"2025","journal-title":"Lancet"},{"key":"10.1016\/j.ejso.2026.111407_bib23","doi-asserted-by":"crossref","DOI":"10.1016\/j.eclinm.2024.102622","volume":"72","author":"Jin","year":"2024","journal-title":"eClinicalMedicine"},{"issue":"5","key":"10.1016\/j.ejso.2026.111407_bib24","doi-asserted-by":"crossref","DOI":"10.3390\/cancers17050894","article-title":"Model predicting survival in intermediate-stage HCC patients reclassified for TACE based on the 2022 BCLC criteria","volume":"17","author":"Kim","year":"2025","journal-title":"Cancers (Basel)"},{"issue":"11","key":"10.1016\/j.ejso.2026.111407_bib25","doi-asserted-by":"crossref","first-page":"4456","DOI":"10.1016\/j.acra.2024.04.045","article-title":"Transarterial chemoembolization (TACE) combined with lenvatinib versus TACE alone in intermediate-stage hepatocellular carcinoma patients beyond up-to-seven criteria: a retrospective, propensity score-matched analysis","volume":"31","author":"Zhou","year":"2024","journal-title":"Acad Radiol"},{"issue":"4","key":"10.1016\/j.ejso.2026.111407_bib26","doi-asserted-by":"crossref","first-page":"1219","DOI":"10.4143\/crt.2024.283","article-title":"Clinical and radiologic predictors of response to atezolizumab-bevacizumab in advanced hepatocellular carcinoma","volume":"56","author":"Choi","year":"2024","journal-title":"Cancer Res Treat"},{"key":"10.1016\/j.ejso.2026.111407_bib27","doi-asserted-by":"crossref","DOI":"10.1177\/17588359221148541","article-title":"Atezolizumab plus bevacizumab in patients with child-pugh B advanced hepatocellular carcinoma","volume":"15","author":"Cheon","year":"2023","journal-title":"Ther Adv Med Oncol"},{"issue":"4","key":"10.1016\/j.ejso.2026.111407_bib28","doi-asserted-by":"crossref","first-page":"807","DOI":"10.1097\/HEP.0000000000000776","article-title":"Sintilimab plus bevacizumab combined with radiotherapy as first-line treatment for hepatocellular carcinoma with portal vein tumor thrombus: a multicenter, single-arm, phase 2 study","volume":"80","author":"Zhu","year":"2024","journal-title":"Hepatology"},{"key":"10.1016\/j.ejso.2026.111407_bib29","article-title":"The clinical significance of sarcopenia in patients with hepatocellular carcinoma treated with lenvatinib and PD-1 inhibitors","volume":"15","author":"Sun","year":"2024","journal-title":"Front Immunol"},{"key":"10.1016\/j.ejso.2026.111407_bib30","article-title":"Efficacy and safety of lenvatinib combined with PD-1 inhibitors plus TACE for unresectable hepatocellular carcinoma patients in China real-world","volume":"12","author":"Li","year":"2022","journal-title":"Front Oncol"},{"issue":"5","key":"10.1016\/j.ejso.2026.111407_bib31","doi-asserted-by":"crossref","first-page":"1188","DOI":"10.1097\/JS9.0000000000000295","article-title":"Irradiation stent with 125 I plus TACE versus sorafenib plus TACE for hepatocellular carcinoma with major portal vein tumor thrombosis: a multicenter randomized trial","volume":"109","author":"Lu","year":"2023","journal-title":"Int J Surg"},{"issue":"5","key":"10.1016\/j.ejso.2026.111407_bib32","doi-asserted-by":"crossref","first-page":"1222","DOI":"10.1097\/JS9.0000000000000256","article-title":"TACE-HAIC combined with targeted therapy and immunotherapy versus TACE alone for hepatocellular carcinoma with portal vein tumour thrombus: a propensity score matching study","volume":"109","author":"Yuan","year":"2023","journal-title":"Int J Surg"},{"issue":"1","key":"10.1016\/j.ejso.2026.111407_bib33","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1200\/JCO.22.00392","article-title":"Lenvatinib combined with transarterial chemoembolization as first-line treatment for advanced hepatocellular carcinoma: a phase III, randomized clinical trial (LAUNCH)","volume":"41","author":"Peng","year":"2023","journal-title":"J Clin Oncol"},{"issue":"25","key":"10.1016\/j.ejso.2026.111407_bib34","doi-asserted-by":"crossref","first-page":"3083","DOI":"10.1002\/sim.3697","article-title":"Balance diagnostics for comparing the distribution of baseline covariates between treatment groups in propensity-score matched samples","volume":"28","author":"Austin","year":"2009","journal-title":"Stat Med"},{"issue":"4","key":"10.1016\/j.ejso.2026.111407_bib35","doi-asserted-by":"crossref","first-page":"387","DOI":"10.1016\/S0895-4356(00)00321-8","article-title":"Validating recommendations for coronary angiography following acute myocardial infarction in the elderly: a matched analysis using propensity scores","volume":"54","author":"Normand","year":"2001","journal-title":"J Clin Epidemiol"},{"issue":"8","key":"10.1016\/j.ejso.2026.111407_bib36","doi-asserted-by":"crossref","first-page":"1492","DOI":"10.1136\/gutjnl-2019-318934","article-title":"Randomised, multicentre prospective trial of transarterial chemoembolisation (TACE) plus sorafenib as compared with TACE alone in patients with hepatocellular carcinoma: TACTICS trial","volume":"69","author":"Kudo","year":"2020","journal-title":"Gut"},{"issue":"1","key":"10.1016\/j.ejso.2026.111407_bib37","doi-asserted-by":"crossref","first-page":"328","DOI":"10.1038\/s41392-025-02427-0","article-title":"Transarterial chemoembolization plus atezolizumab and bevacizumab in patients with intermediate hepatocellular carcinoma: a single-arm, phase 2 trial","volume":"10","author":"Wang","year":"2025","journal-title":"Signal Transduct Target Ther"},{"issue":"5","key":"10.1016\/j.ejso.2026.111407_bib38","doi-asserted-by":"crossref","DOI":"10.3390\/cancers15051568","article-title":"Therapeutic modifications without discontinuation of atezolizumab plus bevacizumab therapy are associated with favorable overall survival and time to progression in patients with unresectable hepatocellular carcinoma","volume":"15","author":"Tokunaga","year":"2023","journal-title":"Cancers (Basel)"},{"issue":"1","key":"10.1016\/j.ejso.2026.111407_bib39","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1186\/s13027-022-00443-1","article-title":"Arterial chemoembolization for patients with hepatocellular carcinoma and elevated lactate dehydrogenase is associated with low survival: a cohort study","volume":"17","author":"Zhuang","year":"2022","journal-title":"Infect Agents Cancer"},{"issue":"5","key":"10.1016\/j.ejso.2026.111407_bib40","doi-asserted-by":"crossref","first-page":"399","DOI":"10.1159\/000526163","article-title":"Atezolizumab plus bevacizumab followed by curative conversion (ABC conversion) in patients with unresectable, TACE-unsuitable intermediate-stage hepatocellular carcinoma","volume":"11","author":"Kudo","year":"2022","journal-title":"Liver Cancer"},{"key":"10.1016\/j.ejso.2026.111407_bib41","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2024.1329634","article-title":"Nomograms confirm serum IL-6 and CRP as predictors of immune checkpoint inhibitor efficacy in unresectable hepatocellular carcinoma","volume":"15","author":"Du","year":"2024","journal-title":"Front Immunol"},{"issue":"23","key":"10.1016\/j.ejso.2026.111407_bib42","doi-asserted-by":"crossref","DOI":"10.3390\/ijms222313051","article-title":"Limitations and possibilities of transarterial chemotherapeutic treatment of hepatocellular carcinoma","volume":"22","author":"Ebeling Barbier","year":"2021","journal-title":"Int J Mol Sci"},{"issue":"2","key":"10.1016\/j.ejso.2026.111407_bib43","doi-asserted-by":"crossref","first-page":"516","DOI":"10.1016\/j.cyto.2013.07.021","article-title":"Change in inflammatory cytokine profiles after transarterial chemotherapy in patients with hepatocellular carcinoma","volume":"64","author":"Kim","year":"2013","journal-title":"Cytokine"},{"key":"10.1016\/j.ejso.2026.111407_bib44","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2021.624789","article-title":"Changes in the peripheral blood treg cell proportion in hepatocellular carcinoma patients after transarterial chemoembolization with microparticles","volume":"12","author":"Ren","year":"2021","journal-title":"Front Immunol"},{"issue":"1","key":"10.1016\/j.ejso.2026.111407_bib45","first-page":"21","article-title":"Changes in the frequency of myeloid-derived suppressor cells after transarterial chemoembolization with gelatin sponge microparticles for hepatocellular carcinoma","volume":"2","author":"Yue","year":"2019","journal-title":"J Interv Med"},{"key":"10.1016\/j.ejso.2026.111407_bib46","doi-asserted-by":"crossref","first-page":"2019","DOI":"10.2147\/JHC.S487472","article-title":"Immune Indicator changes in hepatocellular carcinoma undergoing TACE plus ICIs and Anti-VEGF Antibodies\/TKIs: a prognostic biomarker analysis","volume":"11","author":"Xu","year":"2024","journal-title":"J Hepatocell Carcinoma"}],"container-title":["European Journal of Surgical Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0748798326000260?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0748798326000260?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,4,7]],"date-time":"2026-04-07T22:49:27Z","timestamp":1775602167000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0748798326000260"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,3]]},"references-count":46,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2026,3]]}},"alternative-id":["S0748798326000260"],"URL":"https:\/\/doi.org\/10.1016\/j.ejso.2026.111407","relation":{},"ISSN":["0748-7983"],"issn-type":[{"value":"0748-7983","type":"print"}],"subject":[],"published":{"date-parts":[[2026,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Transarterial chemoembolization combined with immune checkpoint inhibitors and anti-VEGF agents for intermediate HCC: a multicenter study","name":"articletitle","label":"Article Title"},{"value":"European Journal of Surgical Oncology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ejso.2026.111407","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 Elsevier Ltd, BASO ~ The Association for Cancer Surgery, and the European Society of Surgical Oncology. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"111407"}}